Key findings from Asia’s First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors

Dr. Sinh presented Gene Solutions’s real-world data from over 600 Southeast Asian cancerpatients, demonstrating the clinical utility of tumor-informed ctDNA through the K-TRACK test. The assay achieved high sensitivity (75.0%–100.0%) and specificity (87.5%–97.9%) inpredicting recurrence, with detection occurring up to 19 months before imaging incolorectal cancer. It also revealed resistance mutations in lung and breast cancers. Through case-based insights, Dr. Sinh underscored the value of longitudinal MRD trackingin guiding adjuvant therapy, personalizing surveillance, and outperforming conventionalmarkers like CEA.

Key findings from Asia’s First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors

Key findings from Asia’s First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors

Speakers:

Nguyen Duy Sinh

Key findings from Asia’s First Real-World Study of ​ ctDNA-MRD Monitoring in Solid Tumors​

Key findings from Asia’s First Real-World Study of ​ ctDNA-MRD Monitoring in Solid Tumors​

Speakers:

Nguyen Duy Sinh

K-CONNECT APAC 2025

Key findings from Asia’s First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors

Key findings from Asia’s First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors